A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

David A. MacdonaldQueen Elizabeth II Health Sciences Centre, Halifax, NS, CanadaCorrespondence[email protected]

Sarit E. AssoulineJewish General Hospital, McGill University, Montreal, QC, Canada

Joseph BrandweinPrincess Margaret Hospital, University Health Network, Toronto, ON, Canada

Suzanne Kamel-ReidUniversity Health Network, Toronto, ON, Canada

Elizabeth A. EisenhauerNCIC Clinical Trials Group, Kingston, ON, Canada

Stephen CoubanQueen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

Stephen CaplanJewish General Hospital, McGill University, Montreal, QC, Canada

Alison FooNCIC Clinical Trials Group, Kingston, ON, Canada

Wendy WalshNCIC Clinical Trials Group, Kingston, ON, Canada

Brian LeberJuravinski Cancer Centre, Hamilton, ON, Canada

Your download is now in progress and you may close this window